Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.69 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540936 | 1.00 | MAOB (0.69) | MAOBMAOASCN9ABCHEGRM5 | |
| Hydrochloric Acid SCHEMBL31070308 | 0.86 | MAOB (0.68) | MAOBMAOASCN9ABCHE | |
| SCHEMBL10435988 | 0.85 | SLC2A1 (0.58) | MAOBMAOASCN9ABCHE | |
| SCHEMBL5020056 | 0.85 | MAOB (0.72) | MAOBMAOASCN9A | |
| SCHEMBL17604065 | 0.84 | MAOB (0.46) | MAOBMAOASCN9A | |
| SCHEMBL22960183 | 0.83 | MAOB (0.70) | MAOBMAOASCN9A | |
| SCHEMBL2933423 | 0.83 | MAOB (0.81) | MAOBMAOASCN9APPARANR4A2 | |
| SCHEMBL2933427 | 0.83 | MAOB (0.81) | MAOBMAOASCN9APPARANR4A2 | |
| SCHEMBL14329886 | 0.83 | MAOB (0.81) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL15219135 | 0.82 | MAOB (0.65) | MAOBMAOASCN9AGRM5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | MAOB 64/4885MAOA 24/4885SCN9A 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.